MTOR and acute lymphoblastic leukemia: These findings suggest that NSP‐B's anti‐cancer activity in T‐ALL might be partially attributed to its ability to disrupt mTOR‐mediated pathways, offering a novel therapeutic angle in T‐ALL treatment.